Skip to main content Accessibility help

Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder

  • P. A. Ringen (a1) (a2), R. Nesvåg (a3) (a4), S. Helle (a5), T. V. Lagerberg (a1) (a2), E. H. Lange (a2) (a4), E. M. Løberg (a5) (a6), I. Agartz (a4) (a7), O. A. Andreassen (a1) (a2) and I. Melle (a1) (a2)...



Cannabis use disorder is associated with an earlier age at onset and a more severe outcome of schizophrenia spectrum disorders. The role of cannabis use before the onset of illness (premorbid cannabis use) has not been fully investigated. We here examined how amount and type of premorbid cannabis use was associated with the later course of illness including current substance use, symptoms and level of functioning in schizophrenia spectrum disorder.


We used a naturalistic sample of patients with DSM-IV schizophrenia spectrum disorders with a comprehensive history of illness and substance use. Data on premorbid substance use was obtained from comprehensive self-report. The relationship to outcome was investigated using regression models that included current substance use and premorbid functioning.


Pre-schizophrenia cannabis use was significantly associated with more severe psychotic symptoms and impaired functioning. Higher levels of premorbid cannabis use were associated with higher levels of current psychotic symptoms. These associations were independent of current substance use and premorbid functioning. Early use of cannabis (age <17 years) was associated with earlier age at onset of psychosis, independently of potential confounders.


Pre-psychosis cannabis use affects illness outcome in schizophrenia spectrum disorders, and is associated with lower age at onset of psychosis. These findings of independent negative effects of premorbid cannabis use in schizophrenia suggest that a limitation of the general use of cannabis may have beneficial health effects.


Corresponding author

*Address for correspondence: Dr P. A. Ringen, Division of Mental Health and Addiction, Oslo University Hospital HF, Psychosis Research Unit/TOP, Ullevål Hospital, Building 49, P.O. Box 4956 Nydalen, N-0424, Oslo, Norway. (Email:


Hide All
Addington, D, Addington, J, Schissel, B (1990). A depression rating scale for schizophrenics. Schizophrenia Research 3, 247251.
Albert, N, Bertelsen, M, Thorup, A, Petersen, L, Jeppesen, P, Le Quack, P, Krarup, G, Jørgensen, P, Nordentoft, M (2011). Predictors of recovery from psychosis, Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophrenia Research 125, 257266.
Alpar, A, Di Marzo, V, Harkany, T (2015). At the tip of an iceberg, prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry 79, e33–45.
Arndt, S, Tyrrell, G, Flaum, M, Andreasen, NC (1992). Comorbidity of substance abuse and schizophrenia, the role of pre-morbid adjustment. Psychological Medicine 22, 379388.
Auther, AM, McLaughlin, D, Carrion, RE, Nagachandran, P, Correll, CU, Cornblatt, BA (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis, impact on conversion to psychosis and functional outcome. Psychological Medicine 42, 24852497.
Barrowclough, C, Emsley, R, Eisner, E, Beardmore, R, Wykes, T (2013). Does change in cannabis use in established psychosis affect clinical outcome? Schizophrenia Bulletin 39, 339348.
Barrowclough, C, Gregg, L, Lobban, F, Bucci, S, Emsley, R (2015). The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophrenia Bulletin 41, 382390.
Brill, N, Levine, SZ, Reichenberg, A, Lubin, G, Weiser, M, Rabinowitz, J (2009). Pathways to functional outcomes in schizophrenia, the role of premorbid functioning, negative symptoms and intelligence. Schizophrenia Research 110, 4046.
Brill, N, Reichenberg, A, Rabinowitz, J, Harary, E, Lubin, G, Davidson, M, Weiser, M (2007). Accuracy of self-reported premorbid functioning in schizophrenia. Schizophrenia Research 97, 103108.
Cannon-Spoor, HE, Potkin, SG, Wyatt, RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470484.
Compton, MT, Broussard, B, Ramsay, CE, Stewart, T (2011). Pre-illness cannabis use and the early course of nonaffective psychotic disorders, associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophrenia Research 126, 7176.
D'Souza, DC, Abi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G, Gueorguieva, R, Cooper, TB, Krystal, JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia, implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594608.
Davis, GP, Compton, MT, Wang, S, Levin, FR, Blanco, C (2013). Association between cannabis use, psychosis, and schizotypal personality disorder, findings from the National Epidemiologic Survey of Alcohol and Related Conditions. Schizophrenia Research 151, 197202.
Dekker, N, Meijer, J, Koeter, M, Van den Brink, W, Van Beveren, N, Kahn, RS, Linszen, DH, Van Os, J, Wiersma, D, Bruggeman, R, Cahn, W, De Haan, L, Krabbendam, L, Myin-Germeys, I (2012). Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychological Medicine 42, 19031911.
DeRosse, P, Kaplan, A, Burdick, KE, Lencz, T, Malhotra, AK (2010). Cannabis use disorders in schizophrenia, effects on cognition and symptoms. Schizophrenia Research 120, 95100.
Di Forti, M, Sallis, H, Allegri, F, Trotta, A, Ferraro, L, Stilo, SA, Marconi, A, La Cascia, C, Reis Marques, T, Pariante, C, Dazzan, P, Mondelli, V, Paparelli, A, Kolliakou, A, Prata, D, Gaughran, F, David, AS, Morgan, C, Stahl, D, Khondoker, M, MacCabe, JH, Murray, RM (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 15091517.
Filbey, FM, McQueeny, T, DeWitt, SJ, Mishra, V (2015). Preliminary findings demonstrating latent effects of early adolescent marijuana use onset on cortical architecture. Developmental Cognitive Neuroscience 16, 1622.
French, L, Gray, C, Leonard, G, Perron, M, Pike, GB, Richer, L, Seguin, JR, Veillette, S, Evans, CJ, Artiges, E, Banaschewski, T, Bokde, AW, Bromberg, U, Bruehl, R, Buchel, C, Cattrell, A, Conrod, PJ, Flor, H, Frouin, V, Gallinat, J, Garavan, H, Gowland, P, Heinz, A, Lemaitre, H, Martinot, JL, Nees, F, Orfanos, DP, Pangelinan, MM, Poustka, L, Rietschel, M, Smolka, MN, Walter, H, Whelan, R, Timpson, NJ, Schumann, G, Smith, GD, Pausova, Z, Paus, T (2015). Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 72, 10021011.
Green, AI, Drake, RE, Brunette, MF, Noordsy, DL (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry 164, 402408.
Griffith-Lendering, MFH, Wigman, JTW, Prince van Leeuwen, A, Huijbregts, SCJ, Huizink, AC, Ormel, J, Verhulst, FC, Van Os, J, Swaab, H, Vollebergh, WAM (2013). Cannabis use and vulnerability for psychosis in early adolescence – a TRAILS study. Addiction 108, 733740.
Hartz, SM, Pato, CN, Medeiros, H, Cavazos-Rehg, P, Sobell, JL, Knowles, JA, Bierut, LJ, Pato, MT (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71, 248254.
Jockers-Scherubl, MC, Wolf, T, Radzei, N, Schlattmann, P, Rentzsch, J, De Gomez-Carrillo, CA, Kuhl, KP (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 10541063.
Kay, SR, Fiszbein, A, Opler, LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.
Khantzian, EJ (1985). The self-medication hypothesis of addictive disorders, focus on heroin and cocaine dependence. American Journal of Psychiatry 142, 12591264.
Kolliakou, A, Joseph, C, Ismail, K, Atakan, Z, Murray, RM (2011). Why do patients with psychosis use cannabis and are they ready to change their use? International Journal of Developmental Neuroscience 29, 335346.
Lambert, M, Conus, P, Lubman, DI, Wade, D, Yuen, H, Moritz, S, Naber, D, McGorry, PD, Schimmelmann, DG (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica 112, 141148.
Large, M, Di Forti, M, Murray, RM (2015). Cannabis, debated schizophrenia link. Nature 527(7578), 305.
Large, M, Mullin, K, Gupta, P, Harris, A, Nielssen, O (2014). Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Australia and New Zealand Journal of Psychiatry 48, 418432.
Larsen, TK, Friis, S, Haahr, U, Johannessen, JO, Melle, I, Opjordsmoen, S, Rund, BR, Simonsen, E, Vaglum, P, McGlashan, TH (2004). Premorbid adjustment in first-episode non-affective psychosis, distinct patterns of pre-onset course. British Journal of Psychiatry 185, 108115.
Linszen, DH, Dingemans, PM, Lenior, ME (1994). Cannabis abuse and the course of recent-onset schizophrenic P. M. disorders. Archives of General Psychiatry 51, 273279.
Lopez-Larson, MP, Bogorodzki, P, Rogowska, J, McGlade, E, King, JB, Terry, J, Yurgelun-Todd, D (2011). Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behavioral Brain Research 220, 164172.
Malone, DT, Hill, MN, Rubino, T (2010). Adolescent cannabis use and psychosis, epidemiology and neurodevelopmental models. British Journal of Pharmacology 160, 511522.
Manrique-Garcia, E, Zammit, S, Dalman, C, Hemmingsson, T, Andreasson, S, Allebeck, P (2014). Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychological Medicine 44, 25132521.
Margolese, HC, Malchy, L, Negrete, JC, Tempier, R, Gill, K (2004). Drug and alcohol use among patients with schizophrenia and related psychoses, levels and consequences. Schizophrenia Research 67, 157166.
McGrath, J, Welham, J, Scott, J, Varghese, D, Degenhardt, L, Hayatbakhsh, MR, Alati, R, Williams, GM, Bor, W, Najman, JM (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 67, 440447.
McKetin, R, Lubman, DI, Baker, AL, Dawe, S, Ali, RL (2013). Dose-related psychotic symptoms in chronic methamphetamine users, evidence from a prospective longitudinal study. JAMA Psychiatry 70, 319324.
Miettunen, J, Törmänen, S, Murray, GK, Jones, PB, Mäki, P, Ebeling, H, Moilanen, I, Taanila, A, Heinimaa, M, Joukamaa, M, Veijola, J (2008). Association of cannabis use with prodromal symptoms of psychosis in adolescence. British Journal of Psychiatry 192, 470–1.
Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes, a systematic review. Lancet 370(9584), 319328.
National Institute of Health (2016). Adolescent Brain Cognitive Development Study ( Accessed 18 January 2016.
Niemi-Pynttari, JA, Sund, R, Putkonen, H, Vorma, H, Wahlbeck, K, Pirkola, SP (2013). Substance-induced psychoses converting into schizophrenia, a register-based study of 18 478 Finnish inpatient cases. Journal of Clinical Psychiatry 74, e94e99.
Pedersen, G, Hagtvet, KA, Karterud, S (2007). Generalizability studies of the Global Assessment of Functioning-Split version. Comprehensive Psychiatry 48, 8894.
Potvin, S, Joyal, S, Pelletier, P, and Stip, E (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia, A meta-analysis. Schizophrenia Research 100, 242251.
Power, BD, Stefanis, NC, Dragovic, M, Jablensky, A, Castle, D, Morgan, V (2014). Age at initiation of amphetamine use and age at onset of psychosis, the Australian Survey of High Impact Psychosis. Schizophrenia Research 152, 300302.
Ringen, PA, Lagerberg, TV, Birkenaes, AB, Engh, JA, Faerden, A, Jonsdottir, H, Nesvag, R, Friis, S, Opjordsmoen, S, Larsen, F, Melle, I, Andreassen, OA (2007). Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychological Medicine 38, 12411249.
Ringen, PA, Melle, I, Birkenaes, AB, Engh, JA, Faerden, A, Vaskinn, A, Friis, S, Opjordsmoen, S, Andreassen, OA (2008). The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatrica Scandinavica 118, 297304.
Ruiz-Veguilla, M, Barrigón, ML, Hernández, L, Rubio, JL, Gurpegui, M, Sarramea, F, Cervilla, J, Gutiérrez, B, James, A, Ferrin, M (2013). Dose–response effect between cannabis use and psychosis liability in a non-clinical population, Evidence from a snowball sample. Journal of Psychiatric Research 47, 10361043.
Shrout, PE, Fleiss, JL (1979). Intraclass correlations, uses in assessing rater reliability. Psychological Bulletin 86, 420428.
Stefanis, NC, Dragovic, M, Power, BD, Jablensky, A, Castle, D, Morgan, VA (2014). The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophrenia Research 156, 211216.
Stone, JM, Fisher, HL, Major, B, Chisholm, B, Woolley, J, Lawrence, J, Rahaman, N, Joyce, J, Hinton, M, Johnson, S, Young, AH (2014). Cannabis use and first-episode psychosis, relationship with manic and psychotic symptoms, and with age at presentation. Psychological Medicine 44, 499506.
Talamo, A, Centorrino, F, Tondo, L, Dimitri, A, Hennen, J, Baldessarini, RJ (2006). Comorbid substance-use in schizophrenia, relation to positive and negative symptoms. Schizophrenia Research 86, 251255.
Tosato, SA, Lasalvia, A, Bonetto, C, Mazzoncini, R, Cristofalo, D, De Santi, K, Bertani, M, Bissoli, S, Lazzarotto, L, Marrella, G, Lamonaca, D, Riolo, R, Gardellini, F, Urbani, A, Tansella, M, Ruggeri, M (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research 47, 438444.
Valmaggia, LR, Day, FL, Jones, C, Bissoli, S, Pugh, C, Hall, D, Bhattacharyya, S, Howes, O, Stone, J, Fusar-Poli, P, Byrne, M, McGuire, PK (2014). Cannabis use and transition to psychosis in people at ultra-high risk. Psychological Medicine 44, 25032512.
Van Dorn, RA, Desmarais, SL, Scott Young, M, Sellers, BG, Swartz, MS (2012). Assessing illicit drug use among adults with schizophrenia. Psychiatry Research 200, 228236.
Van Gastel, WA, Vreeker, A, Schubart, CD, Maccabe, JH, Kahn, RS, Boks, MP (2014). Change in cannabis use in the general population, a longitudinal study on the impact on psychotic experiences. Schizophrenia Research 157, 266270.
Ventura, JJ, Liberman, RP, Green, MF, Shaner, A, Mintz, J (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research 79, 163173.
Weiss, RD, Najavits, LM, Greenfield, SF, Soto, JA, Shaw, SR, Wyner, D (1998). Validity of substance use self-reports in dually diagnosed outpatients. American Journal of Psychiatry 155, 127128.
Zammit, S, Moore, TH, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders, systematic review. British Journal of Psychiatry 193, 357363.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed